The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...

Susan Wojcicki, a non-smoker and CEO of YouTube, was diagnosed with non-small cell lung cancer in 2022 at the age of 56. She ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

A widely accessible drug commonly used to control blood glucose levels in diabetic patients has the potential to strengthen ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer are surgical excision, chemotherapy, and radiation therapy. Immunotherapy ...

In 2022, the Swiss pharma giant said SKYSCRAPER-01 failed to reach the co-primary goal of progression-free survival. The ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...